Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Entinostat Neuroendocrine (NE) Tumor
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Antonio Fojo
- Target Recruit Count
- 5
- Registration Number
- NCT03211988
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03192111
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03187015
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT03179930
- Locations
- 🇺🇸
Roswell Park Cancer Institute (Data Collection Only), Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Roberto Pili
- Target Recruit Count
- 72
- Registration Number
- NCT03024437
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT03018249
- Locations
- 🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸John Muir Medical Center-Concord Campus, Concord, California, United States
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02936752
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02922946
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02922933
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT02915523
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research, Tampa, Florida, United States
🇺🇸HCA Midwest Health (SCRI Affiliate), Kansas City, Missouri, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.